A BioPhorum member only survey to help gain further insight around how the industry is approaching scaling the production of AAV in suspension HEK- 293 cells from lab to commercial scale.

Dec 2022 | Benchmarking, Cell & Gene Therapy, Commercialization, Deliverable, Deliverables Report
A BioPhorum member only survey to help gain further insight around how the industry is approaching scaling the production of AAV in suspension HEK- 293 cells from lab to commercial scale.
Nov 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Host Cell Proteins and other Bioresidual Impurities
A BioPhorum member survey to gather preliminary information from across the biopharmaceutical industry on the characterization and risk assessment of HCP using mass spectrometry.
Nov 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Host Cell Proteins and other Bioresidual Impurities
A BioPhorum member only survey to share knowledge into how, why and when enzymatic activity assays are performed.
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
BioPhorum member only benchmarking exercise seeking member experience on expectations for mycoplasma testing of cell therapies.
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
BioPhorum member benchmarking survey on testing strategies for AAV and LVV empty, full and partially filled capsids.
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, High Level Analytics
A BioPhorum member survey examining approaches to testing allogenic cell therapies for adventitious viral contaminants.
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, Supply Chain to Patient, Validation
A BioPhorum member only survey to understand viral purification and clearance practices member companies are undertaking in CGT.
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, Validation
A BioPhorum member only survey is to gather information to benchmark what analytical controls member companies are currently using to establish methods to test identity, strength, potency and purity.
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, Validation
A BioPhorum member only benchmarking survey to understand the current challenges and strategies undertaking regarding leveraging process characterization data/use of platforms to accelerate validation.
Oct 2022 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, Regulatory Strategy
A BioPhorum member survey aimed to gather initial industry benchmarking data and interest in defining an industry position on visible particulate control strategy for cell and gene therapies.